部門紹介

研究業績

最終更新日 : 2017年6月19日

目次

  1. 原著論文
  2. 解説・総説や教科書など

原著論文

2017年

T. Nakamura, S. Okabe, H. Yoshida, K. Iida, Y. Ma, S. Sasaki, T. Yamori, K. Shin-ya, I. Nakano, K. Nagasawa, H. Seimiya.
Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole. Sci Rep, 7: 3605 (2017)
T. Mashima, Y Taneda, M.K. Jang, A. Mizutani, Y. Muramatsu, H. Yoshida, A. Sato, N. Tanaka, Y. Sugimoto, H. Seimiya.
mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Oncotarget, in press (2017)
T. Migita, A. Ueda, T. Ohishi, M. Hatano, H. Seimiya, S. Horiguchi, F. Koga and F. Shibasaki.
Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer. Lab Invest, 97: 567-576 (2017)
T. Ohishi, H. Yoshida, M. Katori, T. Migita, Y. Muramatsu, M. Miyake, Y. Ishikawa, A. Saiura, S. Iemura, T. Natsume and H. Seimiya.
Tankyrase-binding protein TNKS1BP1 regulates actin cytoskeleton rearrangement and cancer cell invasion.
Cancer Res, 77: 2328-2338 (2017)
N. Tanaka, T. Mashima, A. Mizutani, A. Sato, A. Aoyama, B. Gong, H. Yoshida, Y. Muramatsu, K. Nakata, M. Matsuura, R. Katayama, S. Nagayama, N. Fujita, Y. Sugimoto and H. Seimiya.
APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer. Mol Cancer Ther, 16, 752-762 (2017)

このページのTOPへ

2016年

D. Hasegawa, S. Okabe, K. Okamoto, I. Nakano, K. Shin-Ya and H. Seimiya.
G-quadruplex ligand-induced DNA damage response coupled with telomere dysfunction and replication stress in glioma stem cells.
Biochemical and biophysical research communications, 471, 75-81 (2016)
Y. Hayakawa, M. Kawada, H. Nishikawa, T. Ochiya, H. Saya, H. Seimiya, R. Yao, M. Hayashi, C. Kai, A. Matsuda, T. Naoe, A. Ohtsu, T. Okazaki, H. Saji, M. Sata, H. Sugimura, Y. Sugiyama, M. Toi and T. Irimura.
Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.
Cancer science, 107, 189-202 (2016)
A. Mizutani, D. Koinuma, H. Seimiya and K. Miyazono.
The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma.
Oncogene, 35, 3514-23 (2016)
T. Nakamura, Y. Ma, K. Iida, T. Ohtake, H. Seimiya and K. Nagasawa.
Design, synthesis and evaluation of an L-Dopa-derived macrocyclic hexaoxazole (6OTD) as a G-quadruplex-selective ligand.
Heterocycles, 92, 305-315 (2016)
R. Ouchi, S. Okabe, T. Migita, I. Nakano and H. Seimiya.
Senescence from glioma stem cell differentiation promotes tumor growth.
Biochemical and biophysical research communications, 470, 275-81 (2016)
M. Suenaga, T. Mashima, N. Kawata, T. Wakatsuki, Y. Horiike, S. Matsusaka, S. Dan, E. Shinozaki, H. Seimiya, N. Mizunuma, K. Yamaguchi and T. Yamaguch.
Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
Oncotarget, 7, 34811-23 (2016)

このページのTOPへ

2015年

K. Hirashima and H. Seimiya.
Telomeric repeat-containing RNA/G-quadruplex-forming sequences cause genome-wide alteration of gene expression in human cancer cells in vivo.
Nucleic acids research, 43, 2022-32 (2015)
T. Mashima, M. Ushijima, M. Matsuura, S. Tsukahara, K. Kunimasa, A. Furuno, S. Saito, M. Kitamura, T. Soma-Nagae, H. Seimiya, S. Dan, T. Yamori and A. Tomida.
Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.
Cancer Science, 106, 909-20 (2015)
H. Seimiya.
Predicting Risk at the End of the End: Telomere G-tail as a Biomarker.
EBioMedicine, 2, 802-3 (2015)
M. Tera, T. Hirokawa, S. Okabe, K. Sugahara, H. Seimiya and K. Shimamoto.
Design and synthesis of a berberine dimer: A fluorescent ligand with high affinity towards G-quadruplexes.
Chemistry, 21, 14519-28 (2015)

このページのTOPへ

2014年

Mashima, T., Soma-Nagae, T., Migita, T., Kinoshita, R., Iwamoto, A., Yuasa, T., Yonese, J., Ishikawa, Y., Seimiya, H.
TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression. Cancer Res. 74, 4888-4897 (2014)
Shimamoto A, Kagawa H, Zensho K, Sera Y, Kazuki Y, Osaki M, Oshimura M, Ishigaki Y, Hamasaki K, Kodama Y, Yuasa S, Fukuda K, Hirashima K, Seimiya H, Koyama H, Shimizu T, Takemoto M, Yokote K, Goto M, Tahara H.
Reprogramming suppresses premature senescence phenotypes of Werner syndrome cells and maintains chromosomal stability over long-term culture. PLoS One. 9, e112900 (2014)
Migita, T., Okabe, S., Ikeda, K., Igarashi, S., Sugawara, S., Tomida, A., Soga, T., Taguchi, R., Seimiya, H.
Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells.
Int J Cancer, 135, 37-47 (2014)
Ohishi, T., Muramatsu, Y., Yoshida, H., Seimiya, H.
TRF1 ensures the centromeric function of Aurora-B and proper chromosome segregation.
Mol Cell Biol, 34, 2464-2478 (2014)

このページのTOPへ

2013年

Hirashima, K., Migita, T., Sato, S., Muramatsu, Y., Ishikawa, Y., Seimiya, H.
Telomere length influences cancer cell differentiation in vivo.
Mol Cell Biol, 33, 2988-2995 (2013)
Iida, K., Majima, S., Nakamura, T., Seimiya, H., Nagasawa, K.
Evaluation of the interaction between long telomeric DNA and macrocyclic hexaoxazole (6OTD) dimer of a G-quadruplex ligand.
Molecules, 18, 4328-4341 (2013)
Migita, T., Okabe, S., Ikeda, K., Igarashi, S., Sugawara, S., Tomida, A., Taguchi, R., Soga, T., Seimiya, H.
Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact.
Am J Pathol, 182, 1800-1820 (2013)
Ushijima, M., Mashima, T., Tomida, A., Dan, S., Saito, S., Furuno, A., Tsukahara, S., Seimiya, H., Yamori, T., Matsuura, M.
Development of a gene expression database and related analysis programs for evaluation of anticancer compounds.
Cancer Sci, 104, 360-368 (2013)

このページのTOPへ

2012年

Deardorff, M.A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., Saitoh, K., Komata, M., Katou, Y., Clark, D., Cole, K.E., De Baere, E., Decroos, C., Di Donato, N., Ernst, S., Francey, L.J., Gyftodimou, Y., Hirashima, K., Hullings, M., Ishikawa, Y., Jaulin, C., Kaur, M., Kiyono, T., Lombardi, P.M., Magnaghi-Jaulin, L., Mortier, G.R., Nozaki, N., Petersen, M.B., Seimiya, H., Siu, V.M., Suzuki, Y., Takagaki, K., Wilde, J.J., Willems, P.J., Prigent, C., Gillessen-Kaesbach, G., Christianson, D.W., Kaiser, F.J., Jackson, L.G., Hirota, T., Krantz, I.D., Shirahige, K.
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle.
Nature, 489, 313-317 (2012)
Ha, G.H., Kim, H.S., Go, H., Lee, H., Seimiya, H., Chung, D.H., Lee, C.W.
Tankyrase-1 function at telomeres and during mitosis is regulated by Polo-like kinase-1-mediated phosphorylation.
Cell Death Differ, 19, 321-332 (2012)
Kawahara, T., Hosoya, T., Tsukamoto, M., Okabe, S., Yamamura, H., Hayakawa, M., Seimiya, H., Takagi, M., Shin-Ya, K.
JBIR-120: a new growth inhibitor of hormone-refractory prostate cancer cells.
J Antibiot, 65, 373-375 (2012)
Miyazaki, T., Pan, Y., Joshi, K., Purohit, D., Hu, B., Demir, H., Mazumder, S., Okabe, S., Yamori, T., Viapiano, M., Shin-ya, K., Seimiya, H., Nakano, I.
Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb.
Clin Cancer Res, 18, 1268-1280 (2012)
Nakamura, T., Iida, K., Tera, M., Shin-Ya, K., Seimiya, H., Nagasawa, K.
A caged ligand for a telomeric g-quadruplex.
Chembiochem, 13, 774-777 (2012)

このページのTOPへ

2011年

Mashima, T., Okabe, S., Seimiya, H.
Molecular pharmacological approach reveals potential new strategies to suppress androgen receptor signaling in prostate cancer.
Mol Cell Pharmacol, 3, 7-12 (2011)
Mashima, T., Seimiya, H.
Role of acyl-CoA synthetases in glioma cell survival and its therapeutic implication.
In Tumors of the central nervous system, Hayat, M.A.e., (Heidelberg, Springer,), 337-340 (2011)
Takahashi, K., Imano, R., Kibe, T., Seimiya, H., Muramatsu, Y., Kawabata, N., Tanaka, G., Matsumoto, Y., Hiromoto, T., Koizumi, Y., Nakazawa, N., Yanagida, M., Yukawa, M., Tsuchiya, E., Ueno, M.
Fission yeast pot1 and recQ helicase are required for efficient chromosome segregation.
Mol Cell Biol, 31, 495-506 (2011)

このページのTOPへ

2010年

Hatsugai, K., Ohishi, T., Sugimoto, Y., Seimiya, H.
Tankyrase-1 assembly to large protein complexes blocks its telomeric function.
FEBS Lett, 584, 3885-3890 (2010)
Kobayashi, Y., Sato, K., Kibe, T., Seimiya, H., Nakamura, A., Yukawa, M., Tsuchiya, E., Ueno, M.
Expression of mutant RPA in human cancer cells causes telomere shortening.
Biosci Biotechnol Biochem, 74, 382-385 (2010)
Mashima, T., Okabe, S., Seimiya, H.
Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mol Pharmacol, 78, 846-854 (2010)
Migita, T., Narita, T., Asaka, R., Miyagi, E., Nagano, H., Nomura, K., Matsuura, M., Satoh, Y., Okumura, S., Nakagawa, K., Seimiya, H., Ishikawa, Y.
Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3.
Am J Pathol, 176, 1756-1766 (2010)
Ohishi, T., Hirota, T., Tsuruo, T., Seimiya, H.
TRF1 mediates mitotic abnormalities induced by Aurora-A overexpression.
Cancer Res, 70, 2041-2052 (2010)
Seki, T., Yuasa, S., Oda, M., Egashira, T., Yae, K., Kusumoto, D., Nakata, H., Tohyama, S., Hashimoto, H., Kodaira, M., Okada, Y., Seimiya, H., Fusaki, N., Hasegawa, M., Fukuda, K.
Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells.
Cell Stem Cell, 7, 11-14 (2010)
Tera, M., Iida, K., Ikebukuro, K., Seimiya, H., Shin-Ya, K., Nagasawa, K.
Visualization of G-quadruplexes by using a BODIPY-labeled macrocyclic heptaoxazole.
Org Biomol Chem, 8, 2749-2755 (2010)
Yashiroda, Y., Okamoto, R., Hatsugai, K., Takemoto, Y., Goshima, N., Saito, T., Hamamoto, M., Sugimoto, Y., Osada, H., Seimiya, H., Yoshida, M.
A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor.
Biochem Biophys Res Commun, 394, 569-573 (2010)

このページのTOPへ

2009年

Mashima, T., Sato, S., Okabe, S., Miyata, S., Matsuura, M., Sugimoto, Y., Tsuruo, T., Seimiya, H.
Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide.
Cancer Sci, 100, 1556-1562 (2009)
Mashima, T., Sato, S., Sugimoto, Y., Tsuruo, T., Seimiya, H.
Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions.
Oncogene, 28, 9-19 (2009)
McCabe, N., Cerone, M.A., Ohishi, T., Seimiya, H., Lord, C.J., Ashworth, A.
Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer.
Oncogene, 28, 1465-1470 (2009)
Schulz, R., Vogel, T., Mashima, T., Tsuruo, T., Krieglstein, K.
Involvement of fractin in TGF-β-induced apoptosis in oligodendroglial progenitor cells.
Glia, 57, 1619-1629 (2009)

このページのTOPへ

2008年

Migita, T., Narita, T., Nomura, K., Miyagi, E., Inazuka, F., Matsuura, M., Ushijima, M., Mashima, T., Seimiya, H., Satoh, Y., Okumura, S., Nakagawa, K., Ishikawa, Y.
ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer.
Cancer Res, 68, 8547-8554 (2008)
Muramatsu, Y., Tahara, H., Ono, T., Tsuruo, T., Seimiya, H.
Telomere elongation by a mutant tankyrase 1 without TRF1 poly(ADP-ribosyl)ation.
Exp Cell Res, 314, 1115-1124 (2008)
Yeung, B.H., Wong, K.Y., Lin, M.C., Wong, C.K., Mashima, T., Tsuruo, T., Wong, A.S.
Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1/2.
Br J Cancer, 99, 283-293 (2008)

このページのTOPへ

2007年

Muramatsu, Y., Ohishi, T., Sakamoto, M., Tsuruo, T., Seimiya, H.
Cross-species difference in telomeric function of tankyrase 1.
Cancer Sci, 98, 850-857 (2007)
Ohishi, T., Tsuruo, T., Seimiya, H.
Evaluation of tankyrase inhibition in whole cells.
Methods Mol Biol, 405, 133-146 (2007)
Tanaka, E., Fukuda, H., Nakashima, K., Tsuchiya, N., Seimiya, H., Nakagama, H.
HnRNP A3 binds to and protects mammalian telomeric repeats in vitro.
Biochem Biophys Res Commun, 358, 608-614 (2007)

このページのTOPへ

2006年

Kimura, H., Katoh, T., Kajimoto, T., Node, M., Hisaki, M., Sugimoto, Y., Majima, T., Uehara, Y., Yamori, T.
Modification of pyrimidine derivatives from antiviral agents to antitumor agents.
Anticancer Res, 26, 91-97 (2006)
Tahara, H., Shin-Ya, K., Seimiya, H., Yamada, H., Tsuruo, T., Ide, T.
G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells.
Oncogene, 25, 1955-1966 (2006)

このページのTOPへ

2005年

Seimiya, H., Muramatsu, Y., Ohishi, T., Tsuruo, T.
Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
Cancer Cell, 7, 25-37 (2005)

このページのTOPへ